Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 28 July 2017

Essilor: Publication of the 2017 Interim Financial Report

Essilor International    

Published: 06:30 CEST 28-07-2017 /GlobeNewswire /Source: Essilor International / : EI /ISIN: FR0000121667


Publication of the 2017 Interim Financial Report



Charenton-le-Pont, France (July 28, 2017 - 6:30 am) - The Essilor International 2017 Interim Financial Report is being published today.


The report comprises the interim consolidated financial statements, the interim management report, the statement by the person responsible for the interim financial report and the auditors' review report on the interim consolidated financial statements.


It can be downloaded from the Company's website, www.essilor.com, in the "Investors / Publications and Downloads" section, or by clicking on:





About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs approximately 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world (as of December 31, 2016). For more information, please visit www.essilor.com.

The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.





Investor Relations and Financial Communications

Phone: +33 (0)1 49 77 42 16


PDF Version of the news release

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Essilor International, 147 rue de Paris, Charenton-Le-Pont FR-94220, France
If you would like to unsubscribe and stop receiving these e-mails click here.